Latest Erbitux Data On Metastatic Colorectal Cancer Presented At WCGIC Underline Benefits In Patients With KRAS Wild-Type Tumors

Latest Erbitux® (cetuximab) data presented today at the World Congress on Gastrointestinal Cancer (WCGIC) reinforce the value of the targeted therapy in the treatment of metastatic colorectal cancer (mCRC) patients with KRAS wild-type (wt) tumors. Results from the CRYSTALa and CELIMb trials have provided further evidence that KRAS mutation status is the current accepted standard predictive biomarker for Erbitux efficacy in patients with mCRC.

More: continued here

Filed under: Colorectal Cancer on June 27th, 2009